Erste Group Bank Has Positive View of Amgen FY2027 Earnings

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at Erste Group Bank raised their FY2027 earnings estimates for shares of Amgen in a research note issued on Tuesday, March 24th. Erste Group Bank analyst H. Engel now expects that the medical research company will earn $23.60 per share for the year, up from their prior estimate of $23.56. Erste Group Bank has a “Buy” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS.

Other research analysts also recently issued reports about the company. Freedom Capital downgraded Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. Mizuho raised their price objective on Amgen from $280.00 to $295.00 and gave the stock an “outperform” rating in a report on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft lifted their price objective on Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. Leerink Partners reiterated a “market perform” rating and set a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. Finally, Wells Fargo & Company raised their price target on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 19th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $354.60.

Amgen Stock Down 0.2%

Shares of NASDAQ AMGN opened at $353.16 on Thursday. The firm has a market cap of $190.38 billion, a P/E ratio of 24.82, a price-to-earnings-growth ratio of 3.51 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen has a 1 year low of $261.43 and a 1 year high of $391.29. The firm’s 50 day moving average price is $362.22 and its 200 day moving average price is $329.40.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen’s payout ratio is currently 70.84%.

Institutional Trading of Amgen

Institutional investors and hedge funds have recently made changes to their positions in the company. Anfield Capital Management LLC raised its holdings in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC lifted its position in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares in the last quarter. Board of the Pension Protection Fund purchased a new position in Amgen in the 4th quarter worth approximately $26,000. Howard Hughes Medical Institute purchased a new position in Amgen in the 2nd quarter worth approximately $32,000. Finally, Manning & Napier Advisors LLC grew its position in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.